文献速递肝胆胰外科

新辅助调强放疗治疗中央型肝细胞癌的2期评估:非随机对照试验

Phase 2 Evaluation of Neoadjuvant Intensity-Modulated Radiotherapy in Centrally Located Hepatocellular Carcinoma: A Nonrandomized Controlled Trial.
PubMed 文献 · JAMA Surg · 2022-01-01

该2期单中心单组前瞻性非随机对照试验评估了新辅助调强放疗(IMRT)后手术在中央型肝细胞癌中的疗效与安全性。

要点

  • 中央型肝细胞癌新辅助IMRT后手术5年总生存率为69.1%。
  • 34.2%患者达到主要病理缓解,其中13.2%为病理完全缓解。
  • 放疗相关3级不良事件发生率为7.9%,未观察到IIIb级及以上手术并发症。

核心结论

  • 新辅助IMRT联合手术在中央型肝细胞癌患者中有效且耐受良好。

主要发现

  • 影像学肿瘤反应:部分缓解16例(42.1%),疾病稳定22例(57.9%)。
  • 13例(34.2%)达到主要病理缓解,其中5例(13.2%)达到病理完全缓解。
  • 中位随访45.8个月,中位总生存未达到,1年、3年、5年总生存率分别为94.6%、75.4%、69.1%。
  • 中位无病生存45.8个月,1年、3年、5年无病生存率分别为70.3%、54.1%、41.0%。
  • 放疗相关3级不良事件3例(7.9%);手术并发症19例次发生于13例(34.2%),其中I-II级12例(31.6%),IIIa级1例(2.6%),无IIIb级及以上并发症。

关键数值与推荐

  • 主要终点为5年总生存率,次要终点包括肿瘤对IMRT的反应、5年无病生存率和治疗相关不良事件。

临床怎么用

  • 对于中央型肝细胞癌,可考虑新辅助IMRT后行肝切除术,需注意放疗相关3级不良事件及手术并发症的监测。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Centrally located hepatocellular carcinoma (HCC) is a special type of HCC whose outcome is unsatisfactory when treated with surgery alone. No standard adjuvant or neoadjuvant treatment for this disease has been established that improves clinical outcomes. OBJECTIVE: To evaluate the effectiveness and safety of adding neoadjuvant intensity-modulated radiotherapy (IMRT) before surgery in patients with centrally located HCC. DESIGN, SETTING, AND PARTICIPANTS: This phase 2, single-center, single-group prospective nonrandomized controlled trial was conducted between December 16, 2014, and January 29, 2019, at the Cancer Institute and Hospital of the Chinese Academy of Medical Sciences in Beijing, China. The last follow-up was on July 30, 2021. Patients with centrally located HCC who underwent neoadjuvant IMRT and surgery were included in the analysis. INTERVENTIONS: Neoadjuvant IMRT followed by hepatectomy. MAIN OUTCOMES AND MEASURES: The primary end point was 5-year overall survival (OS). The secondary end points were tumor response to IMRT, 5-year disease-free survival (DFS), and treatment-related adverse events. RESULTS: Thirty-eight patients (mean [SD] age, 55.6 [9.3] years; 35 male [92.1%] individuals) completed the prescribed neoadjuvant IMRT without interruption. Radiographic tumor response to IMRT before surgery included partial response (16 [42.1%]) and stable disease (22 [57.9%]). Thirteen patients (34.2%) achieved major pathological response, of which 5 (13.2%) achieved pathologic complete response. With a median follow-up of 45.8 months, the median OS was not reached, and the OS rates were 94.6% at 1 year, 75.4% at 3 years, and 69.1% at 5 years. The median DFS was 45.8 months, and DFS rates were 70.3% at 1 year, 54.1% at 3 years, and 41.0% at 5 years. Radiotherapy-related grade 3 adverse events were observed in 3 patients (7.9%). Nineteen operative complications developed in 13 patients (34.2%), including grade I to II complications in 12 patients (31.6%) and grade IIIa complication in 1 patient (2.6%). No grade IIIb or higher operative complications were observed. CONCLUSIONS AND RELEVANCE: Results of this trial suggest that neoadjuvant IMRT plus surgery is effective and well-tolerated in patients with centrally located HCC. These data may inform a future randomized clinical trial of this new treatment strategy. TRIAL REGISTRATION: ClinicalTrials.gov Identifier: NCT02580929.

来源:JAMA Surg,查看原文。版权归原作者所有。

引用

  1. Wu F, Chen B, Dong D, et al. Phase 2 Evaluation of Neoadjuvant Intensity-Modulated Radiotherapy in Centrally Located Hepatocellular Carcinoma: A Nonrandomized Controlled Trial. JAMA Surg. 2022. PMID: 36197682. doi:10.1001/jamasurg.2022.4702

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。